Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer

• Published in: Future oncology (London, England) Vol. 18; no. 20; pp. 2499 - 2510
• Main Authors: Reckamp, Karen L, Lin, Huamao M, Cranmer, Holly, Wu, Yanyu, Zhang, Pingkuan, Walton, Laura J, Kay, Stephen, Cichewicz, Allie, Neupane, Binod, Fahrbach, Kyle, Popat, Sanjay, Camidge, D Ross
• Format: Journal Article
• Language: English
• Published: England 01.06.2022
• Subjects: brigatinib; matching-adjusted indirect comparison; ALK inhibitor; NSCLC; progression-free survival; Bucher ITC; systematic literature review; alectinib
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2022-0194

To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive  -positive non-small-cell lung cancer (NSCLC). Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive -positive NSCLC.